Charles Explorer logo
🇨🇿

JAK2 V617F mutation is a rare event in juvenile myelomonocytic leukemia

Publikace na 2. lékařská fakulta |
2007

Tento text není v aktuálním jazyce dostupný. Zobrazuje se verze "en".Abstrakt

Juvenile myelomonocytic leukemia (JMML) is a clonal myeloproliferative/myelodysplastic disorder of young children. Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy, and a recent report from the European working group on myelodysplastic syndrome in Childhood (EWOG-MDS) indicates an event-free survival (EFS) of 52% at 5 years after HSCT

Klíčová slova